Literature DB >> 34396536

The IL-23/IL-17 axis promotes the formation of retinal neovascularization by activating the NLRP3 inflammasome in macrophages in an experimental retinopathy mouse model.

Ailing Sui1, Xiuping Chen2, Yiyun Yao1, Yixuan Yao1, Xi Shen1, Yanji Zhu1, Bing Xie1.   

Abstract

Retinal neovascularization (RNV), a pathological process shared among diabetic retinopathy, retinopathy of prematurity and other retinopathies, has been widely studied, but the mechanism remains unclear. In this study, the mechanism by which the interleukin (IL)-23/IL-17 axis regulates RNV in oxygen-induced retinopathy (OIR) model mice and in cell experiments in vitro was characterized. In the retinas of OIR mice, IL-23/IL-17 axis activation was increased and regulated RNV formation, and this effect was accompanied by increased macrophage recruitment and nucleotide-binding domain leucine-rich repeat and pyrin domain containing receptor 3 (NLRP3) inflammasome activation. Moreover, inhibiting the IL-23/IL-17 axis reduced the number of macrophage and the expression and activation of NLRP3 inflammasome. On the other hand, recombinant (r) IL-23p19 and rIL-17A promoted the expression and activation of NLRP3 inflammasome, and the proliferation and migration of macrophages. Furthermore, macrophage elimination decreased the activation of IL-23/IL-17 axis and the expression and activation of NLRP3 inflammasome. In summary, our experiments showed that the IL-23/IL-17 axis promoted the formation of RNV by activating the NLRP3 inflammasome in retinal macrophages of an OIR mouse model.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  IL-23/IL-17 axis; NLRP3 inflammasome; macrophage; retinal neovascularization

Mesh:

Substances:

Year:  2021        PMID: 34396536      PMCID: PMC8561108          DOI: 10.1111/imm.13402

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  38 in total

Review 1.  Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation.

Authors:  Robert A Kastelein; Christopher A Hunter; Daniel J Cua
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

Review 2.  A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections.

Authors:  Margriet I van der Reis; Ellen C La Heij; Yvonne De Jong-Hesse; Peter J Ringens; Fred Hendrikse; Jan S A G Schouten
Journal:  Retina       Date:  2011-09       Impact factor: 4.256

Review 3.  Interleukin-17 and type 17 helper T cells.

Authors:  Pierre Miossec; Thomas Korn; Vijay K Kuchroo
Journal:  N Engl J Med       Date:  2009-08-27       Impact factor: 91.245

Review 4.  Anti-angiogenic therapy versus dose-dense paclitaxel therapy for frontline treatment of epithelial ovarian cancer: review of phase III randomized clinical trials.

Authors:  Katrina N Slaughter; Kathleen N Moore; Robert S Mannel
Journal:  Curr Oncol Rep       Date:  2014-11       Impact factor: 5.075

5.  The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.

Authors:  Ivaylo I Ivanov; Brent S McKenzie; Liang Zhou; Carlos E Tadokoro; Alice Lepelley; Juan J Lafaille; Daniel J Cua; Dan R Littman
Journal:  Cell       Date:  2006-09-22       Impact factor: 41.582

Review 6.  IL-23/IL-17 axis in IBD.

Authors:  Massimiliano Sarra; Francesco Pallone; Thomas T Macdonald; Giovanni Monteleone
Journal:  Inflamm Bowel Dis       Date:  2010-10       Impact factor: 5.325

7.  NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components.

Authors:  Sarah L Doyle; Matthew Campbell; Ema Ozaki; Robert G Salomon; Andres Mori; Paul F Kenna; Gwyneth Jane Farrar; Anna-Sophia Kiang; Marian M Humphries; Ed C Lavelle; Luke A J O'Neill; Joe G Hollyfield; Peter Humphries
Journal:  Nat Med       Date:  2012-05       Impact factor: 53.440

Review 8.  Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.

Authors:  Michael Tolentino
Journal:  Surv Ophthalmol       Date:  2011 Mar-Apr       Impact factor: 6.048

Review 9.  Recent advances in IL-22 biology.

Authors:  Lauren A Zenewicz; Richard A Flavell
Journal:  Int Immunol       Date:  2011-03       Impact factor: 4.823

10.  ATN-161 as an Integrin α5β1 Antagonist Depresses Ocular Neovascularization by Promoting New Vascular Endothelial Cell Apoptosis.

Authors:  Ailing Sui; Yisheng Zhong; Anna M Demetriades; Jikui Shen; Ting Su; Yiyun Yao; Yushuo Gao; Yanji Zhu; Xi Shen; Bing Xie
Journal:  Med Sci Monit       Date:  2018-08-22
View more
  2 in total

1.  The IL-23/IL-17 axis promotes the formation of retinal neovascularization by activating the NLRP3 inflammasome in macrophages in an experimental retinopathy mouse model.

Authors:  Ailing Sui; Xiuping Chen; Yiyun Yao; Yixuan Yao; Xi Shen; Yanji Zhu; Bing Xie
Journal:  Immunology       Date:  2021-08-30       Impact factor: 7.397

2.  Altered Expressions of Transfer RNA-Derived Small RNAs and microRNAs in the Vitreous Humor of Proliferative Diabetic Retinopathy.

Authors:  Yan Yang; Wenyun Yue; Nan Wang; Zicong Wang; Bingyan Li; Jun Zeng; Shigeo Yoshida; Chun Ding; Yedi Zhou
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-12       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.